We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Australian Pharmaceutical Industries Limited is a medical distribution business based in Australia. Australian Pharmaceutical Industries shares (API) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Australian Pharmaceutical Industries has a trailing 12-month revenue of around $4 billion. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $1.0136 - $1.5475 |
|---|---|
| 50-day moving average | $1.4324 |
| 200-day moving average | $1.3048 |
| Target price | $1.47 |
| PE ratio | N/A |
| Dividend yield | $0.035 (2.31%) |
| Earnings per share (TTM) | $-0.029 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$1.52
| 1 week (2021-10-07) | -0.33% |
|---|---|
| 1 month (2021-09-17) | 3.75% |
| 3 months (2021-07-17) | 35.11% |
| 6 months (2021-04-16) | 13.01% |
| 1 year (2020-10-16) | 43.40% |
|---|---|
| 2 years (2019-10-17) | 4.83% |
| 3 years (2018-10-17) | -11.63% |
| 5 years (2016-10-17) | -20.63% |
Valuing Australian Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Australian Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Australian Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.53. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Australian Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Australian Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $59.4 million (£0.0 million).
The EBITDA is a measure of a Australian Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4 billion |
|---|---|
| Operating margin TTM | 1.05% |
| Gross profit TTM | $480.5 million |
| Return on assets TTM | 1.64% |
| Return on equity TTM | -2.98% |
| Profit margin | -0.36% |
| Book value | 0.935 |
| Market capitalisation | $748.8 million |
TTM: trailing 12 months
Dividend payout ratio: 1.17% of net profits
Recently Australian Pharmaceutical Industries has paid out, on average, around 1.17% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Australian Pharmaceutical Industries shareholders could enjoy a 2.31% return on their shares, in the form of dividend payments. In Australian Pharmaceutical Industries's case, that would currently equate to about A$0.035 per share.
While Australian Pharmaceutical Industries's payout ratio might seem low, this can signify that Australian Pharmaceutical Industries is investing more in its future growth.
The latest dividend was paid out to all shareholders who bought their shares by 5 May 2021 (the "ex-dividend date").
Australian Pharmaceutical Industries's shares were split on 22 October 2009.
Over the last 12 months, Australian Pharmaceutical Industries's shares have ranged in value from as little as $1.0136 up to $1.5475. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Australian Pharmaceutical Industries's is 0.0799. This would suggest that Australian Pharmaceutical Industries's shares are less volatile than average (for this exchange).
Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails health and beauty products to consumers through a network of Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores in Australia; sells beauty products through Clear Skincare network of clinics in Australia and New Zealand; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and non-invasive aesthetic beauty services. The company was founded in 1910 and is based in Camberwell, Australia.
Shares in the trans-Tasman dairy company are down 55% over the last 12 months.
Shares in the Brisbane-based lender have risen nearly 60% in the last 12 months.
Everything we know about the Tissue Repair IPO, plus information on how to buy in.
This guide will show you step-by-step instructions on how to buy the Illuvium (ILV) token as well as a list of exchanges you can trade it on.
Westpac shares are up 43% over the past 12 months.
Airports, travel agents and pubs are set to soar post lockdown, but should share investors look beyond immediate short-term wins?
Shares in the insurer are up just 10% in the last 12 months.
Everything we know about the Nimy Resources IPO, plus information on how to buy in.
The payment services company’s shares are up 16% in the last year.
Everything we know about the Parabellum Resources IPO, plus information on how to buy in.
